Sunshine Biopharma Inc Total Assets
Sunshine Biopharma Inc total assets. Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) holds total assets worth $33.63 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SBFM market cap for the company's overall valuation and market capitalisation.
Total Assets of Sunshine Biopharma Inc (2007–2025)
Total assets of Sunshine Biopharma Inc from 2007 to 2025. This chart illustrates how Sunshine Biopharma Inc's total assets have evolved over time, based on quarterly financial data. See latest Sunshine Biopharma Inc stock price today for real-time trading data and today's change.
Sunshine Biopharma Inc - Asset Composition Analysis
Sunshine Biopharma Inc Total Assets Breakdown (December 2025)
Sunshine Biopharma Inc total assets breakdown as of December 2025. Sunshine Biopharma Inc's total assets of $33.63 Million consist of 89.3% current assets and 10.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.3% |
| Accounts Receivable | $3.46 Million | 11.5% |
| Inventory | $13.47 Million | 44.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.89 Million | 6.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sunshine Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SBFM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunshine Biopharma Inc's current assets represent 89.3% of total assets in 2025, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 30.3% of total assets in 2025, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 44.8% of total assets.
Sunshine Biopharma Inc Competitors by Total Assets
Key competitors of Sunshine Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Sunshine Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.46 | 5.00 | 5.28 |
| Quick Ratio | 3.30 | 2.66 | 5.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $25.05 Million | $22.28 Million | $2.02 Million |
Sunshine Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Sunshine Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.15 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | $30.08 Million |
| Market Capitalization | $4.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunshine Biopharma Inc's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sunshine Biopharma Inc's assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual total assets of Sunshine Biopharma Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $30.08 Million | -1.57% |
| 2024-12-31 | $30.56 Million | +11.75% |
| 2023-12-31 | $27.35 Million | -7.44% |
| 2022-12-31 | $29.55 Million | +1241.20% |
| 2021-12-31 | $2.20 Million | +110.71% |
| 2020-12-31 | $1.05 Million | +965.27% |
| 2019-12-31 | $98.14K | -91.44% |
| 2018-12-31 | $1.15 Million | +345.30% |
| 2017-12-31 | $257.49K | +299.80% |
| 2016-12-31 | $64.40K | -90.43% |
| 2015-12-31 | $673.26K | +369.42% |
| 2014-12-31 | $143.42K | +359.10% |
| 2013-12-31 | $31.24K | -76.82% |
| 2012-12-31 | $134.79K | +26.64% |
| 2011-12-31 | $106.44K | -48.74% |
| 2010-12-31 | $207.62K | +85.19% |
| 2009-12-31 | $112.12K | +2129.39% |
| 2008-12-31 | $5.03K | -66.24% |
| 2007-12-31 | $14.89K | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more